NDAORALPELLETSPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
MAVYRET (glecaprevir and pibrentasvir) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2021.
Drug data last refreshed 1h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAVYRET (glecaprevir and pibrentasvir) is an oral fixed-dose combination antiviral approved for hepatitis C virus (HCV) treatment. It functions as a P-glycoprotein inhibitor and NS5A inhibitor, directly targeting viral replication machinery. The drug represents a pan-genotypic, short-duration cure-focused regimen for HCV patients.
Peak9.1 years to LOE
Product is in peak commercial phase with strong market penetration; brand teams are focused on maintaining market share and optimizing patient access programs.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Career Relevance
MAVYRET offers career opportunities primarily in commercial, market access, and medical affairs functions supporting a mature, high-volume product with established efficacy. Professionals joining the team will focus on patient access optimization, geographic expansion, and defending market position against generic entry rather than novel development work.
Brand Manager
Worked on MAVYRET at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.